Close Button Icon
Doptelet (avatrombopag) Tablets Logo

You are about to leave doptelethcp.com and go to an external page.

Please note that Sobi is not responsible for the content of the website you are about to visit.

CONTINUE

Go back

This information is intended for healthcare professionals in the United States.

Are you a healthcare professional?

Yes

No
Close Button Icon

Discover the Copay Assistance Program

Eligible commercially insured patients may qualify for the Doptelet Copay Assistance Program

What's the program?

  • Eligible patients may pay as little as $0 for each Doptelet prescription
  • Annual maximum benefit up to $15,000

Eligible patients must:

  • Have commercial insurance that covers Doptelet
  • Not be enrolled in any state or covered by a state or federal healthcare program such as Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD), or TRICARE
  • Be 18 years of age or older
  • Be a resident in the United States or a US Territory
  • Be prescribed Doptelet for an FDA-approved use

How to enroll:

  • Approved pharmacies, healthcare professionals, and Doptelet Connect can enroll patients
  • Patients can enroll themselves as well as their caregivers
  • Please call 1-833-368-2663 Monday–Friday 8 am–8 pm ET for more information

Terms and Conditions

  • Patients pay as little as $0 per prescription. Copay Assistance Program has an annual calendar cap of $15,000
  • Patient has an on-label prescription
  • The Copay Assistance Program is void where prohibited by law, taxes, or restricted
  • This offer is non-transferable, no substitutions are permissible, and this offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
  • Sobi, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice
  • The Copay Assistance Program for Doptelet is not insurance and is not intended to substitute for insurance
  • Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Copay Assistance Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount of assistance received from the Copay Assistance Program
  • Certain information pertaining to your use of the Copay Assistance Program will be shared with Sobi, Inc., the sponsor of the Copay Assistance Program. The information disclosed will include the date the prescription is filled, the number of pills or product dispensed by the pharmacists, and the amount of your copay that will be paid for by using this Copay Assistance Program. For more information, please see the Sobi Privacy Policy at https://sobi-northamerica.com/privacy-policy
  • Acceptance in this Copay Assistance Program is not conditioned on any past, present, or future purchase, including additional doses
  • Enrollment for the Copay Assistance Program is valid through the calendar year
  • Sobi reserves the right to change Copay Assistance Program terms at any time
Close Button Icon
  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
  • Request a Rep
  • For US healthcare professionals only

  • Important Safety Information
  • Prescribing Information
  • Patient Information Leaflet
  • For Patients
Doptelet (avatrombopag) Tablets Logo

For US healthcare professionals only

  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
  • Request a Rep

WANT TO KNOW MORE?
YOU'VE GOT IT

Resources for you

Sign up to learn more about Doptelet

Required field.

Please enter first name.
Please enter last name.
Please enter valid email address.
Please enter valid phone number.
Please enter valid NPI number.
Please enter valid address.
Please enter city.
Please select a state.
Please enter valid ZIP code.
Please indicate that you are a US healthcare professional to continue.
Please accept the Terms and Conditions and Privacy Policy to continue.
Something went wrong, please try again later

For your patients

Scheduling Icon

Patient Dosing & Scheduling Guide

A review of the recommended Doptelet dosing that you can share with your patients

download pdf

Any questions about Doptelet Connect?

Our support specialists can help answer your questions about Doptelet and access options — call us at 833-368-2663
Monday–Friday 8 AM–8 PM ET.

Help patients access Doptelet

Help patients access Doptelet

Doptelet Connect™ is committed to helping eligible patients navigate access to Doptelet.

Learn more
Doptelet Platelet Character Cheerleader Using Megaphone
INDICATION & IMPORTANT
SAFETY INFORMATION

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions

The most common serious adverse reaction reported in DOPTELET-treated patients compared to placebo was hyponatremia (0.7% v. 0%).

Adverse Reactions

The most common adverse reactions (≥3%) in patients with chronic liver disease were: pyrexia, abdominal pain, nausea, headache, fatigue, and peripheral edema.

Postmarketing Experience

Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

For WAC pricing, visit doptelethcp.com/wac-pricing.

Sobi Rare Strength Logo
Terms of Use
Privacy Policy
Contact Us
Unsubscribe

Doptelet is a registered trademark of AkaRx, Inc., a Sobi company.
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
Doptelet Connect is a trademark of AkaRx, Inc.
© 2023 Sobi, Inc. – All rights reserved.

PP-14800v2   03/23

INDICATION & IMPORTANT
SAFETY INFORMATION
Open ISI Button
Close ISI Button

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Scroll To Top Button

This website uses cookies. By continuing to use this website, you consent to our use of these cookies.

Read more about our use of cookies